<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961142</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2007-006016-33</org_study_id>
    <nct_id>NCT00961142</nct_id>
  </id_info>
  <brief_title>Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia</brief_title>
  <acronym>CD3/CD19 Haplo</acronym>
  <official_title>Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility and toxicity of haploidentical allogeneic HCT after a reduced intensity&#xD;
      conditioning regimen with CD3/CD19 depleted grafts. This study enrolls patients with acute&#xD;
      leukemia in complete remission with an indication for allogeneic HCT but without a suitable&#xD;
      HLA-identical donor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 30, 2015</completion_date>
  <primary_completion_date type="Actual">December 30, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment related mortality after haploidentical HCT</measure>
    <time_frame>1 year after HCT</time_frame>
    <description>Cumulative Incidence of treatment related mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1, 2 and 5 years after inclusion</time_frame>
    <description>by Kaplan-Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Engraftment</measure>
    <time_frame>One year after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Toxicity</measure>
    <time_frame>One year after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Disease Free Survival</measure>
    <time_frame>1, 2 and 5 years after inclusion</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)</intervention_name>
    <description>Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with either ALL or AML in CR with an indication for allogeneic HCT according&#xD;
             to the following criteria:&#xD;
&#xD;
          -  AML: high risk patients with one or more of the following risk factors:&#xD;
&#xD;
               -  FLT-3 mutation&#xD;
&#xD;
               -  Complex cytogenetics&#xD;
&#xD;
               -  abn(3q), -5/5q-, -7/7q-, abn(12p), abn(17p)&#xD;
&#xD;
               -  Late CR &gt; induction I&#xD;
&#xD;
               -  Age &gt;60&#xD;
&#xD;
               -  Patients in 2.CR&#xD;
&#xD;
               -  Secondary AML&#xD;
&#xD;
               -  Relapse after a preceding allogeneic HCT from an HLA-identical donor&#xD;
&#xD;
          -  ALL: high risk patients with one or more of the following risk factors:&#xD;
&#xD;
               -  Pro-B-ALL&#xD;
&#xD;
               -  Initial WBC &gt;30.000/ÂµL&#xD;
&#xD;
               -  CR after day 46 after Induction II&#xD;
&#xD;
               -  Complex cytogenetics, t(9,22), t(4,11)&#xD;
&#xD;
               -  Early or mature T-ALL&#xD;
&#xD;
               -  Initially refractory patients with late CR&#xD;
&#xD;
               -  Rising MRD level&#xD;
&#xD;
               -  Patients in 2. CR&#xD;
&#xD;
               -  Relapse after a preceding allogeneic HCT from an HLA-identical donor&#xD;
&#xD;
               -  No HLA-identical donor (not more than 1 antigen mismatch (9/10-Match) or more&#xD;
                  than 2 allelic mismatches by high-resolution typing). Critical cases should be&#xD;
                  discussed with the PI.&#xD;
&#xD;
               -  Age &lt;=65, &gt;=18 years&#xD;
&#xD;
               -  Karnofsky Index &gt;60%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with &gt;5% blasts in BM at the time of transplantation&#xD;
&#xD;
          -  Less than 3 months after preceding HCT&#xD;
&#xD;
          -  CNS involvement with disease&#xD;
&#xD;
          -  History of neurologic impairment such as: seizures, severe peripheral neuropathy,&#xD;
             signs of leukoencephalopathy, CNS infection, multiple intrathecal chemotherapies, CNS&#xD;
             irradiation. In case of heavy pretreatment with irradiation or intrathecal&#xD;
             chemotherapy pretransplant CNS MRI and neurological consultation are mandatory&#xD;
&#xD;
          -  Fungal infections with radiological progression after receipt of amphotericin B or&#xD;
             active triazole for greater than 1 month.&#xD;
&#xD;
          -  Liver function abnormalities with bilirubin &gt;2 mg/dL and elevation of transaminases&#xD;
             higher 2x upper limit of normal.&#xD;
&#xD;
          -  Chronic active viral hepatitis&#xD;
&#xD;
          -  Ejection fraction &lt;40 % on echocardiography&#xD;
&#xD;
          -  Patients with &gt; grade II hypertension by CTC criteria&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min&#xD;
&#xD;
          -  Respiratory failure necessitating supplemental oxygen or DLCO &lt;30%&#xD;
&#xD;
          -  Allergy against murine antibodies&#xD;
&#xD;
          -  HIV-Infection&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential not employing an effective method of birth control during study treatment&#xD;
             and for at least 12 months thereafter. (Women of childbearing potential must have a&#xD;
             negative serum pregnancy test at study entry)&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes,&#xD;
             congestive heart failure, myocardial infarction within 6 months prior to the study,&#xD;
             unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled&#xD;
             infection) which could compromise participation in the study&#xD;
&#xD;
          -  Patients with a history of psychiatric illness or condition which could interfere with&#xD;
             their ability to understand the requirements of the study (this includes&#xD;
             alcoholism/drug addiction)&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Enrollment in an other trial interfering with the endpoints of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang A. Bethge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University Hospital Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Dresden Medical Center</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Marrow Transplantation, University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South West German Cancer Center, University of Tuebingen Medical Center</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsche Klinik fÃ¼r Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wuerzburg Medical Center</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
    <country>Italy</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>http://www.onkologie-tuebingen.de/ifa0.htm</url>
    <description>Homepage BMT-Study Group Tuebingen</description>
  </link>
  <reference>
    <citation>Bethge WA, Faul C, BornhÃ¤user M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, HÃ¤gele M, Handgretinger R, Kanz L. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.</citation>
    <PMID>17869547</PMID>
  </reference>
  <reference>
    <citation>Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, Handgretinger R, Kanz L. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol. 2006 Dec;34(12):1746-52.</citation>
    <PMID>17157172</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Wolfgang Bethge</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Haploidentical Transplantation</keyword>
  <keyword>CD3/CD19 Depletion</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>Reduced Intensity Conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

